



Autolus to manufacture at the Cell and Gene Therapy Catapult – Collaboration to support GMP approval and licensure of the centre

November 22, 2016

London, 22 November 2016 – Autolus Ltd (“Autolus”), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours, and the Cell and Gene Therapy Catapult (“CGT Catapult”) have signed an agreement for Autolus to become the first company to enter the CGT Catapult’s manufacturing centre in Stevenage, UK. CGT Catapult is in part funded by the UK government and dedicated to supporting the growth of the UK cell and gene therapy industry by filling the gap between scientific research and commercialisation.

Autolus will occupy one of the first of six manufacturing modules set up to support commercial scale cell therapy manufacturing. Autolus’ initial activities for setting up and running GMP processes will also facilitate approval and licensure of the centre by the MHRA, which is expected in early 2018.

The CGT Catapult manufacturing centre will enable firms to serve a global market from the UK. The independent modules in the centre have been designed to flex to an autologous, allogeneic or viral vector process and can be adapted to support to any cell or gene therapy company seeking to develop new market ready GMP processes.

Jim Faulkner, Head of Manufacturing, Autolus said:

“We have differentiated ourselves with our technology base and product candidates and the CGT Catapult’s unique operational model allows us to grow our manufacturing capacity, while accessing a range of services provided by the centre. Our manufacturing activities at the CGT Catapult will serve our clinical programs and can support future market entry of successful programs.”

Keith Thompson, CEO, the Cell and Gene Therapy Catapult said:

“We are delighted to welcome Autolus as the first company to collaborate in the centre to manufacture their pipeline of T cell products for the treatment of cancer patients. The vision for our manufacturing centre and the cluster that is forming around it is to enable companies to develop their GMP manufacturing capacity, whilst allowing them to retain total control of their process. It’s an exciting time for this area of cancer therapy and our new facility helps position the UK as a European and global hub for cell and gene therapy manufacturing.”

Notes to editors

Further information:

Autolus – JW Communications
Julia Wilson +44 (0)7818 430877
juliawilsonuk@gmail.com

Cell and Gene Therapy Catapult
Helen MacBain, Head of marketing and communications
+44(0)7891 297018
helen.macbain@ct.catapult.org.uk

For more information on the manufacturing centre:

Video: <https://ct.catapult.org.uk/manufacturing/manufactu...>

Factsheet: <https://ct.catapult.org.uk/manufacturing/manufactu...>

About the Cell and Gene Therapy Catapult

The Cell and Gene Therapy Catapult was established in 2012 as an independent centre of excellence to advance the growth of the UK cell and gene therapy industry, by bridging the gap between scientific research and full-scale commercialisation. With more than 100 employees focusing on cell and gene therapy technologies, we work with our partners in academia and industry to ensure these life-changing therapies can be developed for use in health services throughout the world. We offer leading-edge capability, technology and innovation to enable companies to take products into clinical trials and provide clinical, process development, manufacturing, regulatory, health economics and market access expertise. We aim to make the UK the most compelling and logical choice for UK and international partners to develop and commercialise these advanced therapies. Regenerative medicine is one of the UK government’s “eight great technologies” that support UK science strengths and business capabilities. The Cell and Gene Therapy Catapult works with Innovate UK. For more information go to ct.catapult.org.uk or visit www.gov.uk/innovate-uk.

About Autolus

Autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products based on its proprietary T-cell programming technology. Autolus' shareholders include Syncona LLP, UCL Business PLC, Woodford Investment Management LLP and Arix Bioscience plc. For further information please visit the Company's website at: www.autolus.com